CD274 and neoplasm: The KEYNOTE-024 trial showed that pembrolizumab was associated with longer PFS and OS compared to platinum-based combination chemotherapy in patients with previously untreated advanced NSCLC and a PD-L1 tumor proportion score of 50% or greater [29].